Navigation Links
An international first at the CHUM - Promising treatment in regeneration of the myocardium through the use of stem cells
Date:12/19/2007

MONTREAL, Dec. 19 /PRNewswire/ - The Centre hospitalier de l'Universite de Montreal (CHUM) announces the beginning of a phase II randomized double-blind trial with the potential of providing a therapeutic alternative after a first acute myocardial infarction. One patient has already undergone this technique, which consists of implanting immature stem cells from the bone marrow to regenerate heart muscle. The procedure went smoothly and the patient is doing well. This worldwide first, conducted in collaboration with Hopital Maisonneuve-Rosemont (Montreal, Canada) follows in the footsteps of successful phase I clinical trials carried out in Europe. To date, these preliminary studies have revealed no complications in the subjects treated, after five years of follow-up. These encouraging findings confirm the results of many preliminary experiments carried out on animal models.

Some facts

- Did you know that cardiovascular disease is the primary cause of death

in Western countries?

- Did you know that one hospital bed in five is occupied by someone

suffering from heart disease?

- Did you know that myocardial infarction (heart attack), the most

frequent cause of heart failure, affects over 250,000 patients in

Quebec?

"Drug treatment and heart transplant are among the various techniques that can improve heart function. But because the paucity of organs available remains a major problem, CHUM researchers have worked together to set up this innovative research protocol," states Dr. Samer Mansour, cardiologist at the CHUM, and principal investigator for the trial. One of the aims of this trial is to understand the effect of immature stem cells (CD133+), extracted from the patient's bone marrow in the iliac crest, on the healing process of the heart after a first heart attack. The experiment protocol involves intracoronary injection of CD133+ cells against placebo, in addition to standard medical treatment. The entire process takes place during the same period of hospitalization.

"The study of cell therapy in the case of myocardial lesions is relatively recent and we still have a great deal to learn in this trial," adds Dr Guy Leclerc, head of the CHUM's cardiology service. "Previous studies have demonstrated significant improvement of 7 to 10 % in heart function after implanting several types of bone marrow stem cells. In this trial, we will study these immature cells using the most advanced technologies and state-of-the-art imaging techniques to prepare and transplant these cells into the patient."

Bone marrow cells extracted at the CHUM are transferred to the Laboratoire de therapie cellulaire at Hopital Maisonneuve-Rosemont (HMR) to isolate the most immature stem cells. According to Dr. Denis-Claude Roy, director of the hospital's research centre, "The fact that the stem cells that have been isolated are immature should improve their capacity to repair the heart muscle."

This clinical trial is one of a body of research projects in regenerative medicine and cell therapy currently being carried out at the CHUM. In these studies, Dr. Mansour and Dr. Nicolas Noiseux, co-investigator for the trial and cardiac surgeon, are attempting to better characterize the mechanisms behind the beneficial effects of stem cells used for the treatment of cardiovascular diseases.

Anticipated impact of the procedure

Currently, this procedure applies to patients who have suffered a first extensive infarction and are at risk for complications such as heart failure. The target population could be broadened once the technique has been further refined and the laboratory protocols perfected. The ultimate goal of this minimally invasive and inexpensive technique, compared to heart transplant, is for it to become more commonly performed in hospitals, in the medium term.

The research team includes the following investigators: Drs. Samer Mansour, Denis-Claude Roy, hematologist (HMR), Guy Leclerc, Nicolas Noiseux, cardiac surgeon, and Francois Reeves, cardiologist (CHUM). Stem cell preparation is carried out at the cell therapy laboratory of HMR under the supervision of Dr Roy. "The contribution of HMR is another good example of complementarity and cooperation in research between the institutions of the RUIS de l'Universite de Montreal (UdeM)," states Dr. Denis R. Roy, Director General of the CHUM and president of the UdeM RUIS.

This research protocol was made possible through the collaboration of the Laboratoire de therapie cellulaire of the Hopital Maisonneuve-Rosemont, Miltenyi Biotec, the CHUM Research Centre, its radiology and nuclear medicine departments and its cardiology service, notably through its interventional hemodynamics development fund. Health Canada, Fonds de la recherche en sante du Quebec, and Boston Scientific also contributed to the trial.

About the CHUM

http://www.chumontreal.qc.ca.

For documents on the protocol and the intervention, please visit the CHUM website.


'/>"/>
SOURCE CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. International study strengthens case for daily calcium pill
2. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
3. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
4. LCA Hails International Investigators Studying Lung Cancer
5. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
6. PRA International Adds Dr. Susan Stansfield as Executive Vice President
7. Medical Services International Maintains Pace in Second Quarter
8. Clarity Imaging International, Inc. Rolls Out Mobile DEXA Program
9. International Gateway Insurance Brokers Partners With MEDILINQ
10. Tulane University to receive $14M for international HIV/AIDS program
11. International Database Seeks to Boost Treatment of Altitude Sickness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... , ... August 16, 2017 , ... Paul Vitenas, ... Castle Connolly 2017 Top Doctor. The annual list identifies the nation’s top physicians, in ... Vitenas has made it to the top of Castle Connolly’s coveted ranking. , Castle ...
(Date:8/16/2017)... ... August 16, 2017 , ... SGNA Standards of Infection Control ... cycle, both between patient procedures and before storage, is a requisite practice crucial ... to the prevention of disease transmission and nosocomial infection as cleaning and HLD.” ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... eBook, 9781498499620    ) shares that during the time of a cancer diagnosis, surgery and ... God's love, and all the many ways God shows love to those who ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... an opportunity for men and women to train as hospice volunteers. Volunteers provide ... life-limiting illness. For over 30 years, the agency has trained volunteers to be ...
(Date:8/16/2017)... ... August 16, 2017 , ... Rollon Skin ... anti-aging skincare solutions, recently announced the launch of two new skincare products, Prache ... effective alternative to expensive plastic surgery or in-patient cosmetic dermatological procedures. , “Prache ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... FLINT, Mich. , Aug. 7, 2017 Diplomat ... appointment of Joel Saban as president, effective Aug. ... Paul Urick has decided to pursue other interests and ... period. "During his tenure, Paul has served us in multiple ... Burman,s Specialty Pharmacy in Jun. 2015 and has provided decisive, ...
(Date:8/7/2017)... International plc (NASDAQ: ENDP ) today announced that ... U.S. mesh product liability claims and that it is ... claims at reasonable values. Under the agreements, Endo will ... 2017 and continuing through the fourth quarter of 2019. ... Company intends to increase its mesh product liability accrual ...
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, a ... active in the biopharmaceutical, nutraceutical, and aquacultural feed ... of its lead drug candidates, AGR131.  This drug ... cytokine from the blood of patients suffering from ... inflammatory bowel disease. ...
Breaking Medicine Technology: